![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1439338
³ì³»Àå ¹è¾× ±â±â : ¼¼°è ½ÃÀå ÀλçÀÌÆ®, °æÀï ±¸µµ ¹× ½ÃÀå ¿¹Ãø(2030³â)Glaucoma Drainage Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
¼¼°è ³ì³»Àå ¹è¾× ±â±â ½ÃÀå ±Ô¸ð´Â 2023³â 6¾ï 4,057¸¸ ´Þ·¯, 2030³â¿¡´Â 11¾ï 8,439¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2024-2030³âÀÇ ¿¹Ãø ±â°£ µ¿¾È ¿¬Æò±Õ 11.95% ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ³ì³»Àå ¹è¾× ±â±â ¼ö¿ä Áõ°¡´Â ÁÖ·Î Àü ¼¼°èÀûÀ¸·Î ³ì³»Àå À¯º´·ü Áõ°¡, ´ç´¢º´ ¹× °íÇ÷¾Ð°ú °°Àº »ýȰ½À°üº´ Áõ°¡, ³ëÀÎ Àα¸ÀÇ ºÎ´ã Áõ°¡, Á¦Ç° °³¹ßÀÇ ±â¼ú Çõ½Å µîÀÌ ³ì³»Àå ¹è¾× ±â±â ½ÃÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
³ì³»Àå ¹è¾× ±â±â ½ÃÀå ¿ªÇÐ
³ì³»Àå ¹è¾× ±â±â¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ÀÇ ÁÖ¿ä ¿äÀÎÀº Àü ¼¼°èÀûÀ¸·Î ³ì³»Àå À¯º´·üÀÌ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â Delhi Ophthalmological Society°¡ Á¦°ø ÇÑ µ¥ÀÌÅÍ¿¡ µû¸£¸é ³ì³»ÀåÀº Àü ¼¼°èÀûÀ¸·Î µ¹ÀÌų ¼ö¾ø´Â ½Ç¸íÀÇ ÁÖ¿ä ¿øÀÎÀÔ´Ï´Ù. °°Àº ÀÚ·á¿¡ µû¸£¸é 2020³â Àü ¼¼°è ³ì³»Àå ȯÀÚ ¼ö´Â 7,960¸¸ ¸íÀ¸·Î Ãß»êµË´Ï´Ù. ¶ÇÇÑ ¾Õ¼ ¾ð±ÞÇÑ ÀÚ·á¿¡ µû¸£¸é Àεµ´Â ³ì³»Àå ȯÀÚ°¡ µÎ ¹øÂ°·Î ¸¹Àº Áö¿ªÀÌ µÉ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀεµÀÇ ³ì³»Àå ȯÀÚ À¯º´·üÀº 2020³â¿¡ 1,190¸¸ ¸í¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. µû¶ó¼ ³ì³»Àå À¯º´·ü Áõ°¡´Â ¿¹Ãø ±â°£(2024-2030) µ¿¾È ³ì³»Àå ÀåÄ¡ ½ÃÀåÀ» ¹Ð¾î ºÙÀÏ ¼ö ÀÖ½À´Ï´Ù.
¶ÇÇÑ, ³ì³»Àå ¹è¾× ±â±â ½ÃÀåÀÇ ¼ºÀåÀ» À̲ô´Â ¶Ç ´Ù¸¥ ÁÖ¿ä ¿äÀÎÀº ´ç´¢º´°ú °íÇ÷¾ÐÀÇ À¯º´·ü Áõ°¡°¡ µÉ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â¿¡ ¹ßÇ¥µÈ ¼¼°èº¸°Ç±â±¸(WHO) µ¥ÀÌÅÍ¿¡ µû¸£¸é 2020³â Àü ¼¼°èÀûÀ¸·Î ¾à 4¾ï 2,200¸¸ ¸íÀÌ ´ç´¢º´À» ¾Î°í ÀÖÀ¸¸ç, ¸Å³â ¾à 150¸¸ ¸íÀÌ ´ç´¢º´À» ¾Î°í ÀÖ½À´Ï´Ù. ÀÌó·³ ´ç´¢º´Àº ³ì³»Àå ¹ßº´ °¡´É¼ºÀ» µÎ ¹è·Î Áõ°¡½Ã۰í, Á¶±â¿¡ Ä¡·áÇÏÁö ¾ÊÀ¸¸é ½Ã·Â ÀúÇÏ ¹× ½Ç¸íÀ¸·Î À̾îÁú ¼ö Àֱ⠶§¹®¿¡ ¿¹Ãø ±â°£(2024-2030³â) µ¿¾È ³ì³»Àå ±â±â ½ÃÀå ¼ö¿ä¸¦ Áõ°¡½Ãų ¼ö ÀÖ½À´Ï´Ù.
¶ÇÇÑ 2020³â Pan American Health OrganizationÀÌ ¹ßÇ¥ÇÑ Ãֽе¥ÀÌÅÍ¿¡ µû¸£¸é Àü ¼¼°è ¼ºÀÎ Àα¸ÀÇ 30% ÀÌ»óÀÌ °íÇ÷¾ÐÀ» ¾Î°í ÀÖÀ¸¸ç, Àü ¼¼°èÀûÀ¸·Î 10¾ï ¸í ÀÌ»óÀÌ °íÇ÷¾ÐÀ» ¾Î°í ÀÖ´Ù°í ÇÕ´Ï´Ù. ¶ÇÇÑ ¼¼°èº¸°Ç±â±¸°¡ 2023³â¿¡ ¹ßÇ¥ÇÑ µ¥ÀÌÅÍ¿¡ µû¸£¸é 2020³â Áß±¹¿¡¼´Â ¾à 2¾ï 7,000¸¸ ¸íÀÌ °íÇ÷¾ÐÀ» ¾Î°í ÀÖ´Ù°í ÇÕ´Ï´Ù. ¶ÇÇÑ °íÇ÷¾ÐÀº ´«ÀÇ µ¿¸ÆÀ» ¼Õ»ó½ÃÄÑ ¾È¾Ð »ó½Â¿¡ µû¸¥ Ç÷·ù º¯È¿¡ ÀûÀÀÇÏÁö ¸øÇÏ°Ô ¸¸µé¾î ³ì³»ÀåÀÇ À§Çè ¿äÀÎÀ¸·Î °£Áֵ˴ϴÙ.
¾ÕÀ¸·Î À§ÀÇ ¿äÀεéÀº ¿¹Ãø ±â°£ µ¿¾È ¼¼°è ³ì³»Àå ¹è¾× ±â±â ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀÔ´Ï´Ù.
±×·¯³ª ÀåÄ¡¿Í °ü·ÃµÈ ÇÕº´Áõ°ú ³ì³»Àå ¹è¾×ÀåÄ¡ÀÇ Á¦ÇÑµÈ ±â°£ µ¿¾ÈÀÇ È¿°ú·Î ÀÎÇØ ³ì³»Àå ¹è¾×ÀåÄ¡ ½ÃÀå ¼ºÀå¿¡ ¾î·Á¿òÀ» °ÞÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¶ÇÇÑ, Äڷγª19 ÆÒµ¥¹Í ±â°£ µ¿¾È Àü ¼¼°èÀûÀ¸·Î ³ì³»Àå ¼ö¼ú °Ç¼ö¿Í ±â¾÷ ¼öÀÍ ºÎ¹®ÀÌ Å©°Ô °¨¼ÒÇÏ¿© ³ì³»Àå ¹è¾× ±â±â ½ÃÀåÀÇ ¼ºÀåÀÌ ´Ü±â°£¿¡ Á¦ÇѵǾú½À´Ï´Ù. ±×·¯³ª 2020³â ÇϹݱ⿡ Glaukos CorporationÀÇ Â÷¼¼´ë ³ì³»Àå ¹è¾× ±â±â iStent inject W¸¦ ºñ·ÔÇÑ ¿©·¯ Á¦Ç°ÀÌ Ãâ½ÃµÉ ¿¹Á¤À̱⠶§¹®¿¡ ³ì³»Àå ¹è¾× ±â±â ½ÃÀåÀº ÆÒµ¥¹Í ÀÌÈÄ ½Ã³ª¸®¿À¿¡¼ Àü ¼¼°èÀûÀ¸·Î ȸº¹¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ³ì³»Àå ¹è¾× ±â±â ½ÃÀåÀº º¸´Ù ¸íÈ®ÇÑ ¿¹¹æÀû Á¢±Ù ¹æ½Ä ¹× °¡À̵å¶óÀΰú ÇÔ²² ºÀ¼â ±ÔÁ¦ ¿ÏÈ ¹× ¼±ÅÃÀû ¼ö¼ú Àç°³·Î ÀÎÇØ ´Ù½Ã ¼ºÀåÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ 2020³â ÇϹݱ⿡ Àü ¼¼°èÀûÀ¸·Î ¼ö¸¹Àº Äڷγª19 ¹é½ÅÀÌ ½ÂÀεǰí Åõ¿©µÇ¸é¼ ÀÇ·á ¼ºñ½º¸¦ Æ÷ÇÔÇÑ ´Ù¾çÇÑ ºÐ¾ßÀÇ È°µ¿ÀÌ Å©°Ô ȸº¹µÇ¾î ³ì³»Àå ¹è¾× ±â±â ½ÃÀåÀÇ °ÇÀüÇÑ È¸º¹±â¿¡ Á¢¾îµé ¼ö ÀÖ´Â ±æÀ» ¿¾ú½À´Ï´Ù.
³ì³»Àå ¹è¾× ±â±â ½ÃÀå ºÎ¹® ºÐ¼®
³ì³»Àå ¹è¾× ±â±â ½ÃÀåÀÇ Á¦Ç° ºÎ¹®¿¡¼´Â Àúħ½ÀÀû ³ì³»Àå ¼ö¼ú ÀåÄ¡(MIGS) Ä«Å×°í¸®°¡ 2030³â±îÁö 6¾ï 8,146¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2024-2030³âÀÇ ¿¹Ãø ±â°£ µ¿¾È 11.95%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÌ º¸°í¼´Â ¼¼°è ³ì³»Àå ¹è¼öÀåÄ¡ ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇßÀ¸¸ç, ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, ÃËÁø¿äÀÎ ¹× °úÁ¦, ±â¾÷ ¹× Á¦Ç° ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
Glaucoma Drainage Devices Market By Product Type (Conventional Glaucoma Drainage Devices [Valveless Glaucoma Drainage Devices And Valved Glaucoma Drainage Devices], Minimally Invasive Glaucoma Surgery (Migs) Devices [Schlemm's Canal Migs Devices, Suprachoroidal Migs Devices, And Subconjunctival Migs Devices]), By End-User (Hospitals, Ambulatory Surgical Centers, And Specialty Clinics), by geography, is anticipated to grow at a significant CAGR forecast till 2030 due to rising prevalence of glaucoma and increasing prevalence of diabetes & hypertension
The global glaucoma drainage devices market was valued at USD 640.57 million in 2023, growing at a CAGR of 11.95% during the forecast period from 2024 to 2030, to reach USD 1,184.39 million by 2030. The increase in demand for glaucoma drainage devices is primarily due to the rising prevalence of glaucoma across the globe, increasing lifestyle disorders such as diabetes & hypertension, the growing burden of the old age population, and technical innovation in product development are expected to boost the market for glaucoma drainage devices.
Glaucoma Drainage Devices Market Dynamics:
The key factor responsible for the increasing demand for glaucoma drainage devices is the rising prevalence of glaucoma conditions worldwide. For instance, as per the data provided by the Delhi Ophthalmological Society in 2022, glaucoma is the leading cause of irreversible blindness across the world. As per the same source, in 2020, the global burden of glaucoma was estimated to be 79.6 million. Also, according to the aforementioned source, India is expected to be the second-largest home of glaucoma patients, and the estimated prevalence of glaucoma cases in India was estimated to be 11.9 million in 2020. Therefore, the increasing prevalence of glaucoma could boost the glaucoma devices market during the forecast period (2024-2030).
Further, another key factor that is responsible for the growth of the glaucoma drainage devices market could be the increasing prevalence of diabetes & hypertension. For instance, as per the World Health Organization data published in the year 2023, in 2020, about 422 million people worldwide had diabetes, and about 1.5 million people suffer from diabetes every year. Thus, diabetes doubles the chances of having glaucoma, which can lead to vision loss and blindness if not treated early, which can increase the glaucoma devices market demand during the forecast period (2024-2030).
Furthermore, according to the latest data published by Pan American Health Organization in 2020, hypertension had affected more than 30% of the adult population worldwide, accounting for more than one billion people around the world. Also, as per the data published by World Health Organization in the year 2023, in 2020, about 270 million people were affected by hypertension in China. Moreover, the blood arteries in the eyes may be damaged by hypertension and unable to adjust to changes in blood flow as a result of rising ocular pressure, which is considered to be a risk factor for glaucoma.
Henceforth, the above-mentioned factors will contribute to the global glaucoma drainage devices market growth during the forecasted period.
However, complications associated with the devices and efficacy of glaucoma drainage devices for a limited timeframe are expected to pose a challenge to the glaucoma drainage devices market growth.
Additionally, there was a significant reduction in the glaucoma surgical volume procedures and company revenue segments across the globe during the COVID-19 pandemic, which restricted the glaucoma-drainage device market growth for a brief period. However, due to the launch of several products such as the iStent inject W by Glaukos Corporation, a next-generation glaucoma drainage device, in the second half of 2020, the glaucoma drainage devices market potentially redeem itself across the globe in the post-pandemic scenario. Also, the easing of lockdown restrictions and resumed elective surgeries along with more clear precautionary approaches and guidelines lead to the renewed market growth of glaucoma drainage devices. Moreover, owing to the approval and administration of numerous COVID-19 vaccines across the globe in the second half of 2020, there was a significant improvement in the resumption of activities across various domains, including healthcare services, thereby paving the way for a sound period of recovery for the glaucoma drainage devices market.
Glaucoma Drainage Devices Market Segment Analysis:
Glaucoma Drainage Devices Market By Product Type (Conventional Glaucoma Drainage Devices [Valveless Glaucoma Drainage Devices and Valved Glaucoma Drainage Devices], Minimally Invasive Glaucoma Surgery (MIGS) Devices [Schlemm's Canal MIGS Devices, Suprachoroidal MIGS Devices, and Subconjunctival MIGS Devices]), End-User (Hospitals, Ambulatory Surgical Centers, and Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the product segment of the glaucoma drainage devices market, the Minimally Invasive Glaucoma Surgery devices (MIGS) category is expected to dominate the market and is estimated to grow at a CAGR of 11.95% during the forecast period from 2024-2030 to reach USD 681.46 million by 2030. The MIGS devices are categorized into Schlemm's Canal MIGS Devices, Suprachoroidal MIGS Devices, and Subconjunctival MIGS Devices. Schlemm's canal MIGS devices are used to increase trabecular outflow by bypassing the trabecular meshwork and directing aqueous humor into Schlemm's canal. Since the trabecular meshwork is considered the primary site of resistance to aqueous humor outflow, bypassing this structure and directing aqueous flow from the anterior chamber directly into Schlemm's canal seemed to be a reasonable approach that increases the demand for these devices.
Moreover, as per the various studies, the Intraocular Pressure (IOP)-lowering efficacy of subconjunctival MIGS appears to approach that of traditional filtering surgery, thereby offering the possibility that they might have utility in more advanced or normal-pressure glaucoma. Further, recently, in May 2022, PRESSERFLO, subconjunctival MIGS devices, was approved by Health Canada to reduce in patients with primary open-angle glaucoma (POAG) whose IOP is not controlled when using maximum tolerated glaucoma medications
Hence, all the aforementioned factors will lead to the segmental growth of the glaucoma drainage devices market in the coming years.
North America is expected to dominate the overall Glaucoma Drainage Devices Market:
Among all the regions, North America dominated the market in the year 2023 and is estimated to grow at a CAGR of 11.06% during the forecast period from 2024 to 2030 to reach USD 453.39 million by 2030. This domination can be primarily attributed to the rising cases of lifestyle-related disorders such as diabetes and the rising geriatric population.
For instance, as per the National Diabetics Statistics Report published by the Centers for Disease Control and Prevention (CDC) in the year 2020, about 34.2 million Americans had diabetes 2020. The report further stated that approximately 88 million Americans showed pre-diabetes levels. The CDC considers diabetes to be one of the major risk factors that may lead to glaucoma development. Thus, diabetes doubles the chances of having glaucoma, which can lead to vision loss and blindness if not treated early, which can increase the glaucoma devices market demand during the forecast period (2024-2030).
According to the data published by the World Bank Group in the year 2023, approximately 9,822,231 population in Mexico were aged 65 years and above in 2020. Thus, the geriatric population is more susceptible to developing glaucoma is also expected to raise the demand for glaucoma drainage devices in the upcoming years.
The market presence of key manufacturers such as Johnson & Johnson, Allergan, and others active in manufacturing glaucoma drainage devices will also contribute to the market growth of these devices.
Thus, all the above-mentioned factors are projected to surge the market for glaucoma drainage devices in the region.
Glaucoma Drainage Devices Market Key Players:
Some of the key market players operating in the glaucoma drainage devices market include Johnson & Johnson, AbbVie Inc, Alcon Inc, Glaukos Corporation, Santen Pharmaceutical Co., Ltd, NovaEye Medical Limited, iSTAR Medical SA, Rheon Medical SA, Advanced Ophthalmic Innovations Pte Ltd, New World Medical Inc, Aurolab, and others.
Recent Developmental Activities in the Glaucoma Drainage Devices Market:
In October 2022, Alcon, the world leader in eye care committed to enabling people to see brilliantly, announced the completion of its previously announced acquisition of Ivantis¢ç, maker of the ground-breaking Hydrus¢ç Microstent, a minimally invasive glaucoma surgery (MIGS) tool intended to reduce eye pressure for open-angle glaucoma patients in conjunction with cataract surgery.
In November 2022, iSTAR Medical a MedTech company committed to delivering breakthrough eye care solutions through minimally-invasive implants designed for bio-integration, received European market approval for glaucoma implant MINIject designed to significantly reduce IOP by enhancing aqueous humor outflow from the anterior chamber to the suprachoroidal space.
In May 2022, Santen Canada Inc., a subsidiary of Santen Pharmaceutical Co., a global company focused on developing ophthalmology products, received Health Canada approval for PRESERFLOTM MicroShunt. This surgical device helps drain eye fluid and reduce intraocular pressure (IOP) in patients with POAG.
Key Takeaways from the Glaucoma Drainage Devices Market Report Study:
Target Audience who can be benefited from the Glaucoma Drainage Devices Market Report Study
Frequently Asked Questions for the Glaucoma Drainage Devices Market:
Glaucoma drainage devices have been designed to divert the aqueous humor from the anterior chamber to the external reservoir. A fibrous capsule is formed in about 4-6 weeks after the surgery and regulates the flow. The devices are extensively used in complicated glaucoma, comprising uveitic glaucoma, neovascular glaucoma, and pediatric and developmental glaucoma.
The global glaucoma drainage devices market was valued at USD 640.57 million in 2023, growing at a CAGR of 11.95% during the forecast period from 2024 to 2030, to reach USD 1,184.39 million by 2030.
The major factors driving the demand for glaucoma drainage devices are the rising prevalence of glaucoma across the globe, increasing lifestyle disorders such as diabetes & hypertension, the growing burden of the old age population, and technical innovation in product development.
Some of the key market players operating in the glaucoma drainage devices market include Johnson & Johnson, AbbVie Inc, Alcon Inc, Glaukos Corporation, Santen Pharmaceutical Co., Ltd, NovaEye Medical Limited, iSTAR Medical SA, Rheon Medical SA, Advanced Ophthalmic Innovations Pte Ltd, New World Medical Inc, Aurolab, and others.
Among all the regions, North America is expected to occupy a major share in the overall glaucoma drainage devices market during the forecasted years, 2024-2030. This domination can be primarily attributed to the rising cases of lifestyle-related disorders such as diabetes and the rising geriatric population.